New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis
Official title: Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)
Funded at Oncoarendi Therapeutics, LLC · NIH-11078734 · Data updated 2026-11-12
This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncoarendi Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Groton, United States) |
| Project start | May 1, 2024 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $66,458 |
| NIH project number | 5R43HL174237-02 |
| Project ID | NIH-11078734 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
✕Less likely to help
Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on developing a new oral medication that targets the myocardin-related transcription factor (MRTF) pathway to treat idiopathic pulmonary fibrosis (IPF). The approach aims to create a more effective and safer treatment option compared to existing therapies, which often have limited efficacy and significant side effects. The research involves selecting a promising compound for further studies that could lead to regulatory approval. By addressing the underlying mechanisms of fibrosis, this treatment could potentially modify the disease's progression.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have gone: Previous research has shown promise in targeting the MRTF pathway for fibrosis treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Oncoarendi Therapeutics, LLC
Groton, United States Active
Researchers
- Principal investigator: Golebiowski, Adam — Oncoarendi Therapeutics, LLC
- Study coordinator: Golebiowski, Adam
Related research
Other NIH-funded projects on the same topics.
-
Improving IPF care for Veterans with a new, practical care model
A project to help Veterans with idiopathic pulmonary fibrosis get timely, expert, and age-friendly care using a new care model.
-
New treatment targeting IL-17A for idiopathic pulmonary fibrosis
This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.